Clinical Trial Update: OSCA - Olaparib Standard of CAre Study

View source ↗

Summary

The OSCA trial evaluating olaparib as standard of care in platinum-sensitive recurrent serous ovarian cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Lynparza (olaparib)

Snippet

Sponsor: AstraZeneca | Conditions: Platinum-sensitive Recurrent Serous Ovarian Cancer | Status: COMPLETED